Skip to main content
Fig. 4 | BMC Pulmonary Medicine

Fig. 4

From: Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

Fig. 4

Antimicrobial activity of β-lactamase inhibitor combinations and cefiderocol against carbapenemase-producing CRE stratified by main carbapenemase types. Abbreviations CRE, carbapenem-resistant Enterobacterales; ATM-AVI, aztreonam-avibactam; CAZ-AVI, ceftazidime-avibactam; MEM-VAB, meropenem-vaborbactam; IMI-REL, imipenem-relebactam; MBL, metallo-β-lactamase; Any CPE: Include isolates with KPC, NDM, SME, OXA-48-like, and/or IMP; No CPE, a carbapenemase gene was not identified. * Inhibited at ≤ 8 mg/L

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us